239 related articles for article (PubMed ID: 36233109)
1. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
Tseng LW; Chang JW; Wu CE
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233109
[TBL] [Abstract][Full Text] [Related]
2. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
[TBL] [Abstract][Full Text] [Related]
3. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Mathieu LN; Larkins E; Akinboro O; Roy P; Amatya AK; Fiero MH; Mishra-Kalyani PS; Helms WS; Myers CE; Skinner AM; Aungst S; Jin R; Zhao H; Xia H; Zirkelbach JF; Bi Y; Li Y; Liu J; Grimstein M; Zhang X; Woods S; Reece K; Abukhdeir AM; Ghosh S; Philip R; Tang S; Goldberg KB; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Jan; 28(2):249-254. PubMed ID: 34344795
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
5. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
Kanemura H; Takeda M; Shimizu S; Nakagawa K
Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
[TBL] [Abstract][Full Text] [Related]
6. Absence of cross-toxicity between MET inhibitors in a non-small-cell lung cancer with a MET exon 14 skipping mutation.
Vanderick A; Colinet B
Acta Clin Belg; 2024 Apr; 79(2):148-151. PubMed ID: 38494868
[TBL] [Abstract][Full Text] [Related]
7. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
Sakai H; Morise M; Kato T; Matsumoto S; Sakamoto T; Kumagai T; Tokito T; Atagi S; Kozuki T; Tanaka H; Chikamori K; Shinagawa N; Takeoka H; Bruns R; Straub J; Schumacher KM; Paik PK
Jpn J Clin Oncol; 2021 Aug; 51(8):1261-1268. PubMed ID: 34037224
[TBL] [Abstract][Full Text] [Related]
8. Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations.
Paik PK; Pfeiffer BM; Vioix H; Garcia A; Postma MJ
Adv Ther; 2022 Jul; 39(7):3159-3179. PubMed ID: 35543963
[TBL] [Abstract][Full Text] [Related]
9. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
[TBL] [Abstract][Full Text] [Related]
10. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
11. Capmatinib successfully overcomes tepotinib-induced intolerable peripheral edema.
Kunimasa K; Kawamura T; Tamiya M; Inoue T; Kuhara H; Nishino K; Kumagai T
Thorac Cancer; 2021 Dec; 12(24):3426-3428. PubMed ID: 34695875
[TBL] [Abstract][Full Text] [Related]
12. Tepotinib in Non-Small-Cell Lung Cancer with
Paik PK; Felip E; Veillon R; Sakai H; Cortot AB; Garassino MC; Mazieres J; Viteri S; Senellart H; Van Meerbeeck J; Raskin J; Reinmuth N; Conte P; Kowalski D; Cho BC; Patel JD; Horn L; Griesinger F; Han JY; Kim YC; Chang GC; Tsai CL; Yang JC; Chen YM; Smit EF; van der Wekken AJ; Kato T; Juraeva D; Stroh C; Bruns R; Straub J; Johne A; Scheele J; Heymach JV; Le X
N Engl J Med; 2020 Sep; 383(10):931-943. PubMed ID: 32469185
[TBL] [Abstract][Full Text] [Related]
13. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring
Roth KG; Mambetsariev I; Salgia R
Cold Spring Harb Mol Case Stud; 2020 Dec; 6(6):. PubMed ID: 33335011
[TBL] [Abstract][Full Text] [Related]
14. Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring
Stargardter M; McBride A; Tosh J; Sachdev R; Yang M; Ambavane A; Mittal M; Vioix H; Liu FX
J Med Econ; 2021; 24(1):816-827. PubMed ID: 34126842
[TBL] [Abstract][Full Text] [Related]
15. Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.
Blanc-Durand F; Alameddine R; Iafrate AJ; Tran-Thanh D; Lo YC; Blais N; Routy B; Tehfé M; Leduc C; Romeo P; Stephenson P; Florescu M
Oncologist; 2020 Nov; 25(11):916-920. PubMed ID: 32716573
[TBL] [Abstract][Full Text] [Related]
16. Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
Morise M; Kato T; Matsumoto S; Inoue T; Sakamoto T; Tokito T; Atagi S; Kozuki T; Takeoka H; Chikamori K; Shinagawa N; Tanaka H; Horii E; Adrian S; Bruns R; Johne A; Paik PK; Sakai H
Cancer Sci; 2024 Apr; 115(4):1296-1305. PubMed ID: 38402853
[TBL] [Abstract][Full Text] [Related]
17. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.
Takamori S; Matsubara T; Fujishita T; Ito K; Toyozawa R; Seto T; Yamaguchi M; Okamoto T
Thorac Cancer; 2021 Mar; 12(6):978-980. PubMed ID: 33533182
[TBL] [Abstract][Full Text] [Related]
18. Tepotinib hydrochloride for the treatment of non-small cell lung cancer.
Wu ZX; Li J; Dong S; Lin L; Zou C; Chen ZS
Drugs Today (Barc); 2021 Apr; 57(4):265-275. PubMed ID: 33851690
[TBL] [Abstract][Full Text] [Related]
19. Going After
Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
[TBL] [Abstract][Full Text] [Related]
20. Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
Xiong W; Hietala SF; Nyberg J; Papasouliotis O; Johne A; Berghoff K; Goteti K; Dong J; Girard P; Venkatakrishnan K; Strotmann R
Cancer Chemother Pharmacol; 2022 Jul; 90(1):53-69. PubMed ID: 35771259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
